抑制剂-话题@MedSci

#抑制剂#

1990篇内容 | 3113人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1852471, encodeId=087118524e1ab, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Clin Cancer Res：靶向细胞外基质重构可恢复BRAFi耐药性黑色素瘤对BRAF抑制剂的敏感性, objectType=article, longId=200028, objectId=1381200028b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1381200028b8, replyNumber=0, likeNumber=72, createdTime=2021-05-13, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1381200028b8, moduleTitle=Clin Cancer Res：靶向细胞外基质重构可恢复BRAFi耐药性黑色素瘤对BRAF抑制剂的敏感性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1381200028b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852693, encodeId=56c4185269368, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Hepatol Int:晚期黑色素瘤患者中免疫检查点抑制剂介导的肝炎与肝转移和临床预后的关系, objectType=article, longId=213469, objectId=74a52134694c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74a52134694c, replyNumber=0, likeNumber=86, createdTime=2022-03-16, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74a52134694c, moduleTitle=Hepatol Int:晚期黑色素瘤患者中免疫检查点抑制剂介导的肝炎与肝转移和临床预后的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74a52134694c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852497, encodeId=55f2185249e18, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Gut：定期服用质子泵抑制剂与2型糖尿病风险, objectType=article, longId=201406, objectId=3eb22014065d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3eb22014065d, replyNumber=0, likeNumber=125, createdTime=2020-12-18, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3eb22014065d, moduleTitle=Gut：定期服用质子泵抑制剂与2型糖尿病风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3eb22014065d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852563, encodeId=bce1185256397, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Clin Cancer Res：JAK1抑制剂Itacitinib可有效预防CAR T细胞疗法引发的细胞因子释放综合征, objectType=article, longId=204517, objectId=6bae20451ef6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6bae20451ef6, replyNumber=0, likeNumber=78, createdTime=2021-09-07, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6bae20451ef6, moduleTitle=Clin Cancer Res：JAK1抑制剂Itacitinib可有效预防CAR T细胞疗法引发的细胞因子释放综合征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6bae20451ef6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852520, encodeId=f1211852520b0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=METTL3抑制剂sTC-15治疗急性髓细胞性白血病, objectType=article, longId=202472, objectId=052f2024e20c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=052f2024e20c, replyNumber=0, likeNumber=84, createdTime=2021-04-28, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=052f2024e20c, moduleTitle=METTL3抑制剂sTC-15治疗急性髓细胞性白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=052f2024e20c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852605, encodeId=69aa185260576, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Dig Dis Sci: 质子泵抑制剂对小肠和粪便微生物群落的影响, objectType=article, longId=207201, objectId=8c9f20e2016f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c9f20e2016f, replyNumber=0, likeNumber=73, createdTime=2021-06-22, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c9f20e2016f, moduleTitle=Dig Dis Sci: 质子泵抑制剂对小肠和粪便微生物群落的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c9f20e2016f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852622, encodeId=2ed8185262206, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=基石药业宣布中国选择性RET抑制剂普吉华®（普拉替尼胶囊）获批，为肺癌患者提供治疗新选择, objectType=article, longId=208973, objectId=b4c72089e345, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4c72089e345, replyNumber=0, likeNumber=59, createdTime=2021-03-29, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4c72089e345, moduleTitle=基石药业宣布中国选择性RET抑制剂普吉华®（普拉替尼胶囊）获批，为肺癌患者提供治疗新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4c72089e345)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852526, encodeId=3602185252633, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=补体C5a受体选择性抑制剂Avacopan治疗化脓性汗腺炎（HS）：II期临床试验取得阳性结果, objectType=article, longId=202651, objectId=9ce020265159, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ce020265159, replyNumber=0, likeNumber=0, createdTime=2021-05-19, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ce020265159, moduleTitle=补体C5a受体选择性抑制剂Avacopan治疗化脓性汗腺炎（HS）：II期临床试验取得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ce020265159)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852467, encodeId=af68185246e53, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle= J Clin Oncol：MEK1/2抑制剂Binimetinib治疗低级别浆液性卵巢癌的疗效, objectType=article, longId=199949, objectId=9c171999498a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c171999498a, replyNumber=0, likeNumber=55, createdTime=2020-11-09, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c171999498a, moduleTitle= J Clin Oncol：MEK1/2抑制剂Binimetinib治疗低级别浆液性卵巢癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c171999498a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852524, encodeId=d75c185252438, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=AP&T: 治疗前磁共振肠造影就可预测克罗恩病患者对TNF-α抑制剂的治疗反应, objectType=article, longId=202617, objectId=d29720261e11, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d29720261e11, replyNumber=0, likeNumber=81, createdTime=2021-01-23, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d29720261e11, moduleTitle=AP&T: 治疗前磁共振肠造影就可预测克罗恩病患者对TNF-α抑制剂的治疗反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d29720261e11)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852645, encodeId=de58185264538, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle= 重磅！国内最佳治疗铂敏感及铂耐药复发性卵巢癌的PARP抑制剂帕米帕利获批, objectType=article, longId=210714, objectId=1c60210e1466, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c60210e1466, replyNumber=0, likeNumber=75, createdTime=2022-01-26, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c60210e1466, moduleTitle= 重磅！国内最佳治疗铂敏感及铂耐药复发性卵巢癌的PARP抑制剂帕米帕利获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c60210e1466)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852679, encodeId=b9d218526e9c9, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Lancet子刊 | RET抑制剂--Pralsetinib治疗甲状腺癌，实现生存重磅突破！, objectType=article, longId=212611, objectId=74632126115d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74632126115d, replyNumber=0, likeNumber=68, createdTime=2022-03-07, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74632126115d, moduleTitle=Lancet子刊 | RET抑制剂--Pralsetinib治疗甲状腺癌，实现生存重磅突破！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74632126115d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852484, encodeId=8de8185248437, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=亚盛医药Bcl-2抑制剂再获FDA孤儿药资格认定，治疗慢性淋巴细胞白血病, objectType=article, longId=200423, objectId=5feb2004238f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5feb2004238f, replyNumber=0, likeNumber=70, createdTime=2020-09-15, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5feb2004238f, moduleTitle=亚盛医药Bcl-2抑制剂再获FDA孤儿药资格认定，治疗慢性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5feb2004238f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852470, encodeId=b4c718524e078, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Lancet oncol：PARP抑制剂veliparib联合卡铂-紫杉醇治疗BRCA突变的晚期乳腺癌的疗效, objectType=article, longId=200007, objectId=6f2b20000e60, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f2b20000e60, replyNumber=0, likeNumber=67, createdTime=2021-03-27, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f2b20000e60, moduleTitle=Lancet oncol：PARP抑制剂veliparib联合卡铂-紫杉醇治疗BRCA突变的晚期乳腺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f2b20000e60)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852449, encodeId=7520185244928, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Prostate Cancer P D：5α-还原酶抑制剂治疗患者中PI-RADS评分v.2预测恶性肿瘤情况分析 , objectType=article, longId=198135, objectId=d44f1981358d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d44f1981358d, replyNumber=0, likeNumber=0, createdTime=2020-08-22, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d44f1981358d, moduleTitle=Prostate Cancer P D：5α-还原酶抑制剂治疗患者中PI-RADS评分v.2预测恶性肿瘤情况分析 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d44f1981358d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852661, encodeId=5e6a185266186, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Liver Cancer：多激酶抑制剂二线疗法用于晚期HCC的疗效和安全性, objectType=article, longId=211491, objectId=32e221149157, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32e221149157, replyNumber=0, likeNumber=99, createdTime=2021-10-06, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32e221149157, moduleTitle=Liver Cancer：多激酶抑制剂二线疗法用于晚期HCC的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32e221149157)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852525, encodeId=6f0c185252512, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=BMJ :免疫抑制剂副作用大？科学家发现Treg细胞可抑制免疫！, objectType=article, longId=202626, objectId=77aa20262623, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77aa20262623, replyNumber=0, likeNumber=84, createdTime=2021-10-11, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77aa20262623, moduleTitle=BMJ :免疫抑制剂副作用大？科学家发现Treg细胞可抑制免疫！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77aa20262623)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852434, encodeId=fb0b1852434e4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=JCEM：免疫检查点抑制剂诱导的甲状腺功能异常与体重指数有关, objectType=article, longId=197669, objectId=13fa19e66948, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13fa19e66948, replyNumber=0, likeNumber=102, createdTime=2020-11-02, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13fa19e66948, moduleTitle=JCEM：免疫检查点抑制剂诱导的甲状腺功能异常与体重指数有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13fa19e66948)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852650, encodeId=108c18526502e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=JEADV：Hh通路抑制剂Vismodegib在临床实践中治疗局部晚期基底细胞癌的有效性, objectType=article, longId=211026, objectId=234e21102685, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=234e21102685, replyNumber=0, likeNumber=101, createdTime=2021-06-14, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=234e21102685, moduleTitle=JEADV：Hh通路抑制剂Vismodegib在临床实践中治疗局部晚期基底细胞癌的有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=234e21102685)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852639, encodeId=58a418526393e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=NEJM：白介素17A/17F双重抑制剂Bimekizumab治疗中重度斑块性银屑病, objectType=article, longId=210420, objectId=5536210420a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5536210420a0, replyNumber=0, likeNumber=69, createdTime=2022-03-20, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5536210420a0, moduleTitle=NEJM：白介素17A/17F双重抑制剂Bimekizumab治疗中重度斑块性银屑病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5536210420a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

抑制剂

2020-05-29

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Clin Cancer Res：靶向细胞外基质重构可恢复BRAFi耐药性黑色素瘤对BRAF抑制剂的敏感性

2021-05-13

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Hepatol Int:晚期黑色素瘤患者中免疫检查点抑制剂介导的肝炎与肝转移和临床预后的关系

2022-03-16

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Gut：定期服用质子泵抑制剂与2型糖尿病风险

2020-12-18

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Clin Cancer Res：JAK1抑制剂Itacitinib可有效预防CAR T细胞疗法引发的细胞因子释放综合征

2021-09-07

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

METTL3抑制剂sTC-15治疗急性髓细胞性白血病

2021-04-28

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Dig Dis Sci: 质子泵抑制剂对小肠和粪便微生物群落的影响

2021-06-22

爆笑小医 (审核中...)

前往app查看评论内容

#抑制剂#

基石药业宣布中国选择性RET抑制剂普吉华®（普拉替尼胶囊）获批，为肺癌患者提供治疗新选择

2021-03-29

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

补体C5a受体选择性抑制剂Avacopan治疗化脓性汗腺炎（HS）：II期临床试验取得阳性结果

2021-05-19

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

J Clin Oncol：MEK1/2抑制剂Binimetinib治疗低级别浆液性卵巢癌的疗效

2020-11-09

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

AP&T: 治疗前磁共振肠造影就可预测克罗恩病患者对TNF-α抑制剂的治疗反应

2021-01-23

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

重磅！国内最佳治疗铂敏感及铂耐药复发性卵巢癌的PARP抑制剂帕米帕利获批

2022-01-26

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Lancet子刊 | RET抑制剂--Pralsetinib治疗甲状腺癌，实现生存重磅突破！

2022-03-07

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

亚盛医药Bcl-2抑制剂再获FDA孤儿药资格认定，治疗慢性淋巴细胞白血病

2020-09-15

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Lancet oncol：PARP抑制剂veliparib联合卡铂-紫杉醇治疗BRCA突变的晚期乳腺癌的疗效

2021-03-27

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Prostate Cancer P D：5α-还原酶抑制剂治疗患者中PI-RADS评分v.2预测恶性肿瘤情况分析

2020-08-22

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Liver Cancer：多激酶抑制剂二线疗法用于晚期HCC的疗效和安全性

2021-10-06

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

BMJ :免疫抑制剂副作用大？科学家发现Treg细胞可抑制免疫！

2021-10-11

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

JCEM：免疫检查点抑制剂诱导的甲状腺功能异常与体重指数有关

2020-11-02

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

JEADV：Hh通路抑制剂Vismodegib在临床实践中治疗局部晚期基底细胞癌的有效性

2021-06-14

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

NEJM：白介素17A/17F双重抑制剂Bimekizumab治疗中重度斑块性银屑病

2022-03-20

科室
- - 订阅+
  - 更多科室
工具
服务